1. A1.28 Synovial fibroblasts suppress TH1, but not TH2 or TH17 cells, through tryptophan metabolism. (13th February 2015) Authors: Tykocinski, LO; Lauffer, AM; Bohnen, A; Krienke, S; Tretter, T; Adam, I; Mohapatra, SR; Saikali, P; Löhning, M; Neidhart, M; Gay, S; Oezen, I; Platten, M; Opitz, CA; Lorenz, HM Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 1 Page Start: A12 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. KS01.3.A Tumoral MHC class II expression in gliomas drives T cell exhaustion. (9th September 2021) Authors: Chih, Y; Sahm, K; Sadik, A; Bunse, T; Trautwein, N; Pusch, S; Stevanovic, S; Opitz, C; Deimling, A; Wick, W; Sahm, F; Bunse, L; Platten, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii3 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. KS01.6.A Comparative analysis of the immune compartment in human glioblastoma and IDH-mutant WHO grade 4 astrocytoma reveals profound differences in microglia phenotypes. (9th September 2021) Authors: Sankowski, R; Friedrich, M; Bunse, L; Heiland, H H; Platten, M; Prinz, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii4 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. KS05.6.A Oral DNA vaccination targeting VEGFR2 combined with the anti-PD-L1 antibody avelumab in patients with progressive glioblastoma - final results. NCT03750071. (5th September 2022) Authors: Wick, W; Wick, A; Chinot, O; Sahm, F; von Deimling, A; Jungk, C; Mansour, M; Podola, L; Lubenau, H; Platten, M Journal: Neuro-oncology Issue: Volume 24(2022)Supplement 2 Page Start: ii6 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. OS06.4A Identification of T cell receptors targeting ZFTA-RELA fusion-positive ependymoma. (9th September 2021) Authors: Kehl, N; Friedrich, M; Kilian, M; Zheng, T; Pajtler, K; Bunse, L; Platten, M Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii9 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. OS12.4.A MHC class II-restricted transgenic T cell receptor therapy targeting mutant capicua transcriptional repressor in experimental gliomas. (9th September 2021) Authors: Kilian, M; Friedrich, M; Sanghvi, K; Green, E; Pusch, S; von Deimling, A; Wick, W; Sahm, F; Platten, M; Bunse, L Journal: Neuro-oncology Issue: Volume 23: Supplement 2 (2021) Page Start: ii15 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. OS2.2 Highly personalized peptide vaccination for patients with newly diagnosed glioblastoma: the GAPVAC trial. (19th September 2018) Authors: Dietrich, P; Wick, W; Hilf, N; Frenzel, K; Gouttefangeas, C; Platten, M; thor Straten, P; Lassen, U; Rodon, J; Bukur, V; Admon, A; van der Burg, S H; von Deimling, A; Kroep, J R; Martinez-Ricarte, F; Okada, H; Ottensmeier, C H; Ponsati, B; Poulsen, H S; Stevanovic, S Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii219 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. OS6.4 NOA-16: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group evaluating a mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas. (19th September 2018) Authors: Platten, M; Schilling, D; Bunse, L; Wick, A; Bunse, T; Riehl, D; Green, E; Sanghvi, K; Karapanagiotou-Schenkel, I; Harting, I; Sahm, F; Steinbach, J; Weyerbrock, A; Hense, J; Misch, M; Krex, D; Setvanovic, S; Tabatabai, G; von Deimling, A; Schmitt, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. P01.013 Long-term analyses of the NOA-08 randomized phase III trial of temozolomide versus radiotherapy for elderly patients with malignant astrocytomas. (19th September 2018) Authors: Wick, A; Kessler, T; Platten, M; Meisner, C; Bamberg, M; Herrlinger, U; Felsberg, J; Weyerbrock, A; Seidel, C; Steinbach, J P; Sabel, M; Vesper, J; Debus, J; Sahm, F; Meixensberger, J; Ketter, R; Mayer-Steinacker, R; von Deimling, A; Reifenberger, G; Weller, M Journal: Neuro-oncology Issue: Volume 20(2018)Supplement 3 Page Start: iii230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗